Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis

References

• Singal R, Ginder GD. DNA methylation. Blood 1999; 93: 4059–70
   PubMed Web of Science ®Google Scholar
• Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription?. Trends Genet 1997; 13: 444–9
   PubMed Web of Science ®Google Scholar
• Bartolomei MS, Tilghman SM. Genomic imprinting in mammals. Annu Rev Genet 1997; 31: 493–525
   PubMed Web of Science ®Google Scholar
• Nakao M, Sasaki H. Genomic imprinting: significance in development and diseases and the molecular mechanisms. J Biochem 1996; 120: 467–73
   PubMedGoogle Scholar
• Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 1998; 93: 305–8
   PubMed Web of Science ®Google Scholar
• Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990; 33: 1665–73
   PubMed Web of Science ®Google Scholar
• Balada E, Ordi-Ros J, Vilardell-Tarrés M. DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 127–36
   Google Scholar
• Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 2002; 59: 241–57
   PubMed Web of Science ®Google Scholar
• Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998; 19: 219–20
   PubMed Web of Science ®Google Scholar
• Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247–57
   PubMed Web of Science ®Google Scholar
• Fujita N, Takebayashi S, Okumura K, Kudo S, Chiba T, Saya H, et al. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol Cell Biol 1999; 19: 6415–26
   PubMed Web of Science ®Google Scholar
• Bird AP, Wolffe AP. Methylation-induced repression: belts, braces, and chromatin. Cell 1999; 99: 451–4
   PubMed Web of Science ®Google Scholar
• Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl 2000; 35: 78–83
   PubMedGoogle Scholar
• Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998; 18: 6538–47
   PubMed Web of Science ®Google Scholar
• Januchowski R, Prokop J, Jagodzinski PP. Role of epigenetic DNA alterations in the pathogenesis of systemic lupus erythematosus. J Appl Genet 2004; 45: 237–48
   PubMedGoogle Scholar
• Sekigawa I, Kawasaki M, Ogasawara H, et al. DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med 2006; 6: 99–106
   PubMed Web of Science ®Google Scholar
• Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 2007; 179: 6352–8
   PubMed Web of Science ®Google Scholar
• Lu Q, Kaplan M, Ray D, Ray D, Zacharek S, Gutsch D, et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1282–91
   PubMed Web of Science ®Google Scholar
• Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupus-like disease in syngeneic mice. J Clin Invest 1996; 97: 2866–71
   PubMed Web of Science ®Google Scholar
• Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005; 174: 6212–19
   PubMed Web of Science ®Google Scholar
• Oelke K, Lu Q, Richardson D, Wu A, Deng C, Hanash S, et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 2004; 50: 1850–60
   PubMed Web of Science ®Google Scholar
• Lu Q, Ray D, Gutsch D, Richardson B. Effect of DNA methylation and chromatin structure on ITGAL expression. Blood 2002; 99: 4503–8
   PubMedGoogle Scholar
• Yung R, Chang S, Hemati N, Johnson K, Richardson B. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997; 40: 1436–43
   PubMed Web of Science ®Google Scholar
• Harmon KR, Leatherman JW. Respiratory manifestations of connective tissue disease. Semin Respir Infect 1988; 3: 258–73
   PubMedGoogle Scholar
• Takada K, Suzuki K, Matsumoto M, Okada M, Nakanishi T, Horikoshi H, et al. Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies. Scand J Rheumatol 2008; 37: 360–4
   PubMed Web of Science ®Google Scholar
• Magalh MB, da Silva LM, Voltarelli JC, Donadi EA, Louzada-Junior P. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007; 36: 442–7
   PubMedGoogle Scholar
• Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 2007; 36: 291–8
   PubMed Web of Science ®Google Scholar
• Paran D, Fireman E, Levartovsky D, Elkayam O, Kaufman I, Litinsky I, et al. Pulmonary dysfunction in systemic lupus erythematosus and anti-phospholipid syndrome patients. Scand J Rheumatol 2007; 36: 285–90
   PubMed Web of Science ®Google Scholar
• Li CH, Li YC, Xu PS, Hu X, Wang CY, Zou GL. Clinical significance of anti-glomerular basement membrane antibodies in a cohort of Chinese patients with lupus nephritis. Scand J Rheumatol 2006; 35: 201–8
   PubMed Web of Science ®Google Scholar
• Gould T, Tikly M, Asherson R, Loizou S, Singh S. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 29–34
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–40
   PubMed Web of Science ®Google Scholar
• Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001; 44: 735–6
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 20;292: 403–7
   Google Scholar
• Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48: 746–56
   PubMed Web of Science ®Google Scholar
• Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Rosa-Leyva M, Vilardell-Tarrés M. Transcript levels of DNA methyltransferases DNMT1, DNMT3A and DNMT3B in CD4+ T cells from patients with systemic lupus erythematosus. Immunology 2008; 124: 339–47
   PubMed Web of Science ®Google Scholar
• Oelke K, Richardson B. Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int Rev Immunol 2004; 23: 315–31
   PubMed Web of Science ®Google Scholar
• Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 2007; 179: 5553–63
   PubMed Web of Science ®Google Scholar
• Jin SG, Jiang CL, Rauch T, Li H, Pfeifer GP. MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing. J Biol Chem 2005; 280: 12700–9
   PubMedGoogle Scholar
• Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 2003; 22: 7130–6
   PubMedGoogle Scholar
• Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 2002; 297: 403–5
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271–9
   PubMed Web of Science ®Google Scholar